Aptinyx Reports Results of NYX-2925 in P-IIb Study for the Treatment of Painful Diabetic Peripheral Neuropathy

Published: Apr 8, 2022 | Tags: Aptinyx, NYX-2925, P-IIb Study, Painful, Diabetic Peripheral Neuropathy

VYNE Reports Results of FMX114 in P-Ib Portion of a P-Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

Published: Apr 8, 2022 | Tags: VYNE, FMX114, P-Ib/IIa Trial, Atopic Dermatitis

Tonix Reports the First Patient Enrollment in the P-III (RESILIENT) Study of TNX-102 SL for the Management of Fibromyalgia

Published: Apr 8, 2022 | Tags: Tonix, P-III, RESILIENT Study, TNX-102 SL, Fibromyalgia

Janssen Reports New Analysis of Xarelto (rivaroxaban) + Aspirin from the P-III (VOYAGER PAD) Trial for PAD and Co-Morbid Conditions

Published: Apr 8, 2022 | Tags: Janssen, Xarelto, rivaroxaban, Aspirin, P-III, VOYAGER PAD Trial, PAD, Co-Morbid Conditions

Propella Signs a License Agreement with Jiangsu Aosaikang to Develop and Commercial CGS-200-5 for the Treatment of Pain in Greater China

Published: Apr 8, 2022 | Tags: Propella, Jiangsu Aosaikang, CGS-200-5, Pain Greater China

Jazz Entered into a License Agreement with Werewolf to Develop WTX-613 for the Treatment of Cancer Using PREDATOR Protein Engineering Technology

Published: Apr 8, 2022 | Tags: Jazz, Werewolf, WTX-613, PREDATOR, Protein, Engineering Technology

Pregene Signs an Exclusive License Agreement with CellPoint to Develop and Commercialize PRG-1801 for the Treatment of R/R Multiple Myeloma

Published: Apr 7, 2022 | Tags: Pregene, CellPoint, PRG-1801, Hematological Indications

Pfizer to Acquire ReViral for ~$525M

Published: Apr 7, 2022 | Tags: Pfizer, Acquire, ReViral, ~$525M

Regeneron and Sanofi’s Dupixent (dupilumab) Receive EC’s Approval for Children with Severe Asthma with Type 2 Inflammation

Published: Apr 7, 2022 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, EC, Approval, Children, Asthma, Type 2 Inflammation

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder

Published: Apr 7, 2022 | Tags: BioXcel Therapeutics, Igalmi, dexmedetomidine, US, FDA, Approval, Agitation, Schizophrenia, Bipolar I or II Disorder

Novartis’ Vijoice (alpelisib) Receives the US FDA’s Approval for the Treatment of PIK3CA-Related Overgrowth Spectrum

Published: Apr 7, 2022 | Tags: Novartis, Vijoice, alpelisib, US, FDA, Approval, PIK3CA, Overgrowth Spectrum

Harbour BioMed Signs Out-License Agreement with AstraZeneca for HBM7022 to Treat Solid Tumors Using HBICE Platform

Published: Apr 7, 2022 | Tags: Harbour BioMed, Out-License, Agreement, AstraZeneca, HBM7022, Solid Tumors, HBICE Platform

Innovent’s Pemazyre (pemigatinib) Receives the NMPA’s Approval for the Treatment of Locally Advanced or Metastatic Cholangiocarcinoma

Published: Apr 6, 2022 | Tags: Innovent, Pemazyre, pemigatinib, NMPA, Approval, Cholangiocarcinoma

Evozyne Entered into a Research Collaboration and License Agreement with Takeda to Develop Gene Therapies for the Treatment of Rare Genetic Diseases

Published: Apr 6, 2022 | Tags: Evozyne, Takeda, Gene Therapies, Rare Genetic Diseases, Protein Engineering Platform

ViGeneron Signs Target-Specific Collaboration and Option Agreement with Regeneron to Develop & Commercialize AAV Based Gene Therapies for Inherited Retinal Disease

Published: Apr 6, 2022 | Tags: ViGeneron, Regeneron, Gene Therapies, Inherited Retinal Disease

Theravance Biopharma Reports Results of Ampreloxetine in P-III (Study 0170) Study for Symptomatic Neurogenic Orthostatic Hypotension

Published: Apr 6, 2022 | Tags: Theravance Biopharma, Ampreloxetine, P-III, Study 0170, Symptomatic Neurogenic Orthostatic Hypotension

Dialectic’s DT2216 Receives the US FDA’s Fast Track Designation for Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Published: Apr 6, 2022 | Tags: Dialectic, DT2216, US FDA’s Fast Track Designation, Peripheral, Cutaneous, T-Cell Lymphoma

Allergan Reports Results of Vuity in P-III (VIRGO) Trial for the Treatment of Presbyopia or Age-Related Blurry Near Vision

Published: Apr 6, 2022 | Tags: Allergan, Vuity, P-III, VIRGO Trial, Presbyopia, Age-Related, Blurry Near Vision

Imara to Discontinue P-IIb (Ardent & Forte) Trial of Tovinontrine (IMR-687) for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Published: Apr 5, 2022 | Tags: Imara, P-IIb, Ardent, Forte Trial, Tovinontrine, IMR-687, Sickle Cell Disease, Beta-Thalassemia

BMS’ Opdivo (nivolumab) Receives the EC’s Approval as Adjuvant Treatment for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma

Published: Apr 5, 2022 | Tags: BMS, Opdivo, nivolumab, EC, Approval, Muscle-Invasive Urothelial Carcinoma

argenx Presents Interim Results of Vyvgart (efgartigimod alfa-fcab) in P-III (ADAPT+) Trial for Generalized Myasthenia Gravis at AAN 2022

Published: Apr 5, 2022 | Tags: argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADAPT+ Trial, Generalized Myasthenia Gravis, AAN 2022

Abbott’s Aveir VR Leadless Pacemaker System Receives the US FDA’s Approval for the Treatment of Slow Heart Rhythms

Published: Apr 5, 2022 | Tags: Abbott, Aveir VR Leadless, Pacemaker System, US, FDA, Approval, Slow Heart Rhythms

Protalix BioTherapeutics and Chiesi Report Results of PRX-102 in P-III (BALANCE) Trial for the Treatment of Fabry Disease

Published: Apr 5, 2022 | Tags: Protalix BioTherapeutics, Chiesi, PRX-102, P-III, BALANCE Trial, Fabry Disease

Immunocore’s Kimmtrak (tebentafusp) Receives the EC’s Approval for the Treatment of Unresectable or Metastatic Uveal Melanoma

Published: Apr 5, 2022 | Tags: Immunocore, Kimmtrak, tebentafusp, EC, Approval, Unresectable, Metastatic, Uveal Melanoma

Junshi Biosciences’ TAB009/JS009 Receives the US FDA’s Approval for the Treatment of Advanced Solid Tumors

Published: Apr 4, 2022 | Tags: Junshi Biosciences, TAB009, JS009, US, FDA, Approval, Advanced Solid Tumors

BridgeBio Pharma Presents Updated Results of Acoramidis (AG10) in P-II OLE Study for Transthyretin Amyloid Cardiomyopathy at ACC 2022

Published: Apr 4, 2022 | Tags: BridgeBio Pharma, Acoramidis, AG10, P-II, OLE Study, Transthyretin Amyloid Cardiomyopathy, ACC, 2022

Sanofi & Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Dupixent (dupilumab) for Eosinophilic Esophagitis

Published: Apr 4, 2022 | Tags: Sanofi, Regeneron, US, FDA, Acceptance, sBLA, Priority Review, Dupixent, dupilumab, Eosinophilic Esophagitis

Ionis and AstraZeneca Reports Results of P-IIb (ETESIAN) Study of ION449 for the Treatment of Hypercholesterolemia at ACC 2022

Published: Apr 4, 2022 | Tags: Ionis, P-IIb, ETESIAN Study, ION449, Hypercholesterolemia, ACC 2022

Innovent Presents Results of IBI306 in P-III (CREDIT-2) Study for the Treatment of Heterozygous Familial Hypercholesterolemia at ACC 2022

Published: Apr 4, 2022 | Tags: Innovent, IBI306, P-III, CREDIT-2 Study, Heterozygous Familial Hypercholesterolemia, ACC 2022

BMS Presents Results of Mavacamten in (EXPLORER-LTE) Cohort of the (MAVA-LTE) Study for Symptomatic Obstructive Hypertrophic Cardiomyopathy at ACC 2022

Published: Apr 4, 2022 | Tags: BMS, Mavacamten, EXPLORER-LTE Cohort, MAVA-LTE Study, Symptomatic, Obstructive, Hypertrophic Cardiomyopathy

Related Post: PharmaShots Weekly Snapshots (March 28 – April 01, 2022)